Risk-stratified venous thromboembolism (VTE) prophylaxis guidelines in oncology use a validated clinical risk score, based on cancer type and laboratory parameters (hemoglobin, leukocyte count, platelet count, BMI), to identify ambulatory cancer patients at sufficiently elevated thrombotic risk to warrant pharmacologic prophylaxis with direct oral anticoagulants or low molecular weight heparin, rather than applying prophylaxis universally. This reflects a broader evidence-based-medicine principle in hematology-oncology: balancing an intervention's benefit (reduced thrombotic events) against its risk (bleeding) at the population level, with guideline recommendations calibrated to the strength and recency of supporting trial evidence.
Risk-stratified venous thromboembolism (VTE) prophylaxis guidelines in oncology use a validated clinical risk score, based on cancer type and laboratory parameters (hemoglobin, leukocyte count, plate…